Ranbaxy's repeat violation elicits swift FDA action--API Cut Off From US

 

Its key API plant is cut off from the U.S., joining three banned drug formulation plants

January 27, 2014 | By Eric Palmer

Read more: Ranbaxy's repeat violation elicits swift FDA action - FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/story/ranbaxys-repeat-violation-elicits-swift-fda-action/2014-01-27#ixzz2rkhuimOp
Subscribe at FiercePharma Manufacturing